AbbVie’s $11B Apogee Bet: Can Zumilokibart Cure Its Humira Hangover?
(SeaPRwire) – By: Christian Pierce
AbbVie is staring down a ticking clock. Its top earner, Humira, is bleeding market share to biosimilars. Skyrizi and Rinvoq are picking up the slack now, but their growth won’t last forever. The company needs a new blockbuster to secure its immunology future—and it’s betting $10.9 billion on Apogee Therapeutics to deliver it.
AbbVie is in advanced talks to acquire clinical-stage biotech Apogee in an all-cash deal worth $10.9 billion. The offer marks a 60% premium to Apogee’s June 18 closing price of $90.38. Reuters reports an announcement could come as early as June 22, though neither company has confirmed the talks. This would be AbbVie’s largest acquisition since its 2019 $63 billion purchase of Allergan. Unlike Allergan, which brought approved products and steady revenue, Apogee has no commercial drugs on the market. Its entire pipeline rests on one lead candidate: zumilokibart. This antibody targets IL-13, a cytokine that drives skin inflammation in atopic dermatitis. Trial data shows it may only require twice-yearly dosing, a stark contrast to up to 26 injections per year with some existing treatments. JPMorgan analyst Chris Schott reiterated his Buy rating on ABBV after news of the talks surfaced. He called the deal a strong strategic fit, pointing to AbbVie’s deep immunology experience as key to commercializing zumilokibart if approved. Schott also noted that zumilokibart could compete directly with Dupixent, the blockbuster drug co-marketed by Sanofi and Regeneron that dominates the atopic dermatitis market. On Friday, ABBV stock fell over 2% while APGE gained around 2%. TipRanks gives ABBV a Strong Buy consensus, with 16 Buys and 5 Holds over the past three months, and a $254.71 price target implying roughly 17.65% upside.
AbbVie’s top three immunology drugs—Skyrizi, Rinvoq, and Humira—generated $30.4 billion combined in 2025, up 14% year over year. But Humira’s decline is accelerating as biosimilars eat into its market. Skyrizi and Rinvoq are growing fast, but their runway is limited. AbbVie has turned to buying early-stage assets instead of waiting for internal candidates to mature. Last year, it paid up to $2.1 billion for Capstan Therapeutics, a Phase 1 autoimmune cell therapy developer. Apogee is a bigger and riskier bet than any previous acquisition. AbbVie is essentially buying into Apogee’s Phase 3 trial for zumilokibart before any regulatory outcome is known. Apogee already secured up to $1.3 billion in financing from Blackstone Life Sciences in May to fund that trial. The $11 billion price tag reflects zumilokibart’s future potential, not Apogee’s current value—its market cap stood at roughly $6.8 billion before news of the deal broke. If zumilokibart gets approved, AbbVie will leverage its sales and marketing muscle to challenge Dupixent’s dominance. It could expand the drug’s use to asthma and COPD, tapping into larger patient pools. If the trial fails, AbbVie will be left with a $11 billion hole in its balance sheet and still searching for a replacement for Humira. This deal sets a new bar for big pharma’s pursuit of clinical-stage biotechs. Competitors like Pfizer and Merck will likely accelerate their own acquisition strategies to avoid falling behind.
Author bio: Christian Pierce is a chief financial columnist and markets commentator, specializing in biotech M&A and pharmaceutical pipeline strategy.